Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $1.50 for the day, up 10.29% from the previous closing price of $1.36. In other words, the price has increased by $10.29 from its previous closing price. On the day, 2.23 million shares were traded.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.02 while its Price-to-Book (P/B) ratio in mrq is 0.37.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $11.91, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 12.04%, while the 200-Day Moving Average is calculated to be -40.54%.
Shares Statistics:
A total of 71.95M shares are outstanding, with a floating share count of 55.63M. Insiders hold about 22.69% of the company’s shares, while institutions hold 76.55% stake in the company.
